Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 1.00 |
| ▸ | DHCR24 | Q15392 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232490 | 1.00 | TRPV1 (1.00) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL27233899 | 1.00 | TRPV1 (1.00) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL27233901 | 1.00 | TRPV1 (1.00) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL34473503 | 1.00 | TRPV1 (1.00) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL6900716 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL1703700 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL22150349 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL21748185 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL10149106 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 | |
| SCHEMBL14419156 | 0.88 | TRPV1 (0.78) | TRPV1DHCR24ALDH1A1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260014075-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST PHARM CO LTD (KR) | 2026-01-15 | — | — | US | claimed |
| US-20260000624-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST PHARM CO LTD (KR) | 2026-01-01 | — | — | US | claimed |
| US-12447160-B2 | Topical treatment of wounds with statins and cholesterol for scar reduction | NORTHWESTERN UNIVERSITY (US) | 2025-10-21 | — | — | US | claimed |
| US-20250214953-A1 | SULFIDE-CONTAINING IONIZABLE LIPID AND LIPID NANOPARTICLE INCLUDING THE SAME | SurgiNex Co., Ltd. (KR) | 2025-07-03 | — | — | US | claimed |
| CN-119889423-A | Method for analyzing mechanism of preventing and treating enteritis of houttuynia cordata based on network pharmacology and molecular docking | 湖北省农业科学院畜牧兽医研究所 | 2025-04-25 | — | — | CN | claimed |
| US-20250089726-A1 | BOTANICAL BASED BIO-STIMULANT, BIO-ACARICIDAL COMPOSITIONS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2025-03-20 | — | — | US | claimed |
| US-20240415129-A1 | BOTANICAL BASED BIO-INSECTICIDAL COMPOSITIONS FOR CONTROLLING PESTS AND IMPROVING THE PLANT PHYSIOLOGICAL PROCESS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2024-12-19 | — | — | US | claimed |
| EP-4467134-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST Pharm Co., Ltd. (KR) | 2024-11-27 | — | — | EP | claimed |
| EP-4467135-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST Pharm Co., Ltd. (KR) | 2024-11-27 | — | — | EP | claimed |
| EP-1059851-B1 | STABLE HOMOGENEOUS EMULSIFIER-FREE SUSPENSION, PREPARATION METHOD AND USES IN FOOD COMPOSITIONS | GERVAIS DANONE SA (FR) | 2002-05-08 | — | — | EP | claimed |
| WO-2002034241-A2 | COMPOUNDS COMPRISING A PHYTOSTEROL AND/OR PHYTOSTANOL MOIETY AND ASCORBIS ACID AND USE THEREOF AS WEIGHT REGULATING AGENTS | FORBES MEDI-TECH INC. (CA) | 2002-05-02 | — | — | WO | claimed |
| EP-1181006-A1 | METHODS FOR REGULATING THE CONDITION OF MAMMALIAN KERATINOUS TISSUE VIA TOPICAL APPLICATION OF PHYTOSTEROL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-27 | — | — | EP | claimed |
| EP-1059851-A1 | STABLE HOMOGENEOUS EMULSIFIER-FREE SUSPENSION, PREPARATION METHOD AND USES IN FOOD COMPOSITIONS | COMPAGNIE GERVAIS-DANONE (FR) | 2000-12-20 | — | — | EP | claimed |
| WO-2000069404-A1 | METHODS FOR REGULATING THE CONDITION OF MAMMALIAN KERATINOUS TISSUE VIA TOPICAL APPLICATION OF PHYTOSTEROL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000061694-A1 | METHOD FOR MANUFACTURING FAT-SOLUBLE PHYTOSTEROL OR PHYTOSTANOL ESTER OF UNSATURATED FATTY ACID | EUGENE SCIENCE, INC. (KR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000052029-A1 | WATER-SOLUBLE STEROL DERIVATIVE FOR INHIBITING CHOLESTEROL ABSORPTION AND PROCESS FOR PREPARING THE SAME | EUGENE SCIENCE INC. (KR) | 2000-09-08 | — | — | WO | claimed |
| WO-1999044442-A1 | STABLE HOMOGENEOUS EMULSIFIER-FREE SUSPENSION, PREPARATION METHOD AND USES IN FOOD COMPOSITIONS | COMPAGNIE GERVAIS DANONE (FR) | 1999-09-10 | — | — | WO | claimed |
| EP-0587374-A2 | Sulfated sterol glycosides and their use against viral infections. | VIROSTAT (NA) NV (NA) | 1994-03-16 | — | — | EP | claimed |
| US-4400295-A | REACTION PRODUCT OF A FATTY ACID, AMINO ACID AND A SECONDARY COMPOUND | LOIRE COSMETICS CO., LTD. (JP) | 1983-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000624-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME | SGMS1, SGMS2, NSUN3 | TRPV1 2978/4885DHCR24 700/4885ALDH1A1 448/4885 |
| US-20260014075-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME | LDLR, CETP, NPC1 | TRPV1 3759/4885DHCR24 443/4885ALDH1A1 887/4885 |
| US-20250214953-A1 | SULFIDE-CONTAINING IONIZABLE LIPID AND LIPID NANOPARTICLE INCLUDING THE SAME | PTDSS2, ABHD16A, SGMS1 | TRPV1 1160/4885DHCR24 4133/4885ALDH1A1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.